Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Post by andoon Oct 23, 2018 7:48pm

86 Views

Post# 28860610

Tons of cash in the bank now

Dilution of the stock will never happen. When I have through the last few recessions and slow times the only sector that ever did good was the Pharma sector. New top line drugs knocked it out of the park. There would be no way I'd be selling of ACST before the trial period ended seeing whare this baby will be. Amarin hits 52 week high after high. We could move 10 fold essy. Looking so far to busting through 5.00 Ando

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023